Anti-SARS-CoV-2 antibody levels and kinetics of vaccine response: potential role for unresolved inflammation following recovery from SARS-CoV-2 infection.
Adult
Antibodies, Viral
/ blood
BNT162 Vaccine
/ administration & dosage
Biomarkers
/ blood
C-Reactive Protein
/ immunology
COVID-19
/ epidemiology
Cohort Studies
Female
Health Personnel
/ statistics & numerical data
Humans
Immunoglobulin G
/ blood
Inflammation
/ immunology
Kinetics
Logistic Models
Male
Middle Aged
Pandemics
/ prevention & control
SARS-CoV-2
/ immunology
Vaccination
/ methods
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
received:
30
09
2021
accepted:
20
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
The immune response after SARS-CoV-2 vaccine administration appears to be characterized by high inter-individual variation, even in SARS-CoV-2 positive subjects, who could have experienced different post-infection, unresolved conditions. We monitored anti-SARS-CoV-2 IgG levels and kinetics along with circulating biomarkers in a cohort of 175 healthcare workers during early immunization with COVID-19 mRNA-LNP BNT162b2 vaccine, to identify the associated factors. Subjects with a previous SARS-CoV-2 infection were characterized by higher BMI and CRP levels and lower neutrophil count with respect to naïve subjects. Baseline IgG levels resulted associated with CRP independently on BMI and inflammatory diseases. Among 137 subjects undergoing vaccination and monitored after the first and the second dose, three kinetic patterns were identified. The pattern showing a rapid growth was characterized by higher IgG levels at baseline and higher CRP and MCHC levels than negative subjects. Subjects previously exposed to SARS-CoV-2 showed higher levels of CRP, suggesting persistence of unresolved inflammation. These levels are the main determinant of IgG levels at baseline and characterized subjects belonging to the best performing, post-vaccine antibody kinetic pattern.
Identifiants
pubmed: 35013457
doi: 10.1038/s41598-021-04344-y
pii: 10.1038/s41598-021-04344-y
pmc: PMC8749002
doi:
Substances chimiques
Antibodies, Viral
0
Biomarkers
0
Immunoglobulin G
0
C-Reactive Protein
9007-41-4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
385Subventions
Organisme : Fondazione Umberto Veronesi (Umberto Veronesi Foundation)
ID : COVID-19 Insieme per la ricerca 2020
Organisme : Regione Lombardia (Region of Lombardy)
ID : DG-Welfare n. 7082/2020
Informations de copyright
© 2022. The Author(s).
Références
J Formos Med Assoc. 2021 Jun;120(6):1405-1407
pubmed: 33380377
Sci Rep. 2021 Feb 26;11(1):4741
pubmed: 33637783
Clin Exp Immunol. 2021 Jun;204(3):310-320
pubmed: 33534923
Diagnostics (Basel). 2021 May 25;11(6):
pubmed: 34070341
Science. 2021 Feb 26;371(6532):916-921
pubmed: 33479118
Eur J Intern Med. 2021 Jul;89:97-103
pubmed: 34090748
Int J Epidemiol. 2021 May 17;50(2):400-409
pubmed: 33434269
Vaccines (Basel). 2021 May 18;9(5):
pubmed: 34070196
J Infect Public Health. 2021 May;14(5):561-569
pubmed: 33848885
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
J Med Internet Res. 2021 Feb 22;23(2):e23390
pubmed: 33534722
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Vaccines (Basel). 2021 May 06;9(5):
pubmed: 34066475
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Vaccines (Basel). 2021 Jun 01;9(6):
pubmed: 34205932
Sports Med. 2021 Aug;51(8):1673-1686
pubmed: 33877614
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33211672
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Diagnostics (Basel). 2020 Aug 21;10(9):
pubmed: 32825629
Infect Dis (Lond). 2021 Oct;53(10):737-754
pubmed: 34024217
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
Cochrane Database Syst Rev. 2020 Nov 20;11:CD006207
pubmed: 33215698
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Clin Infect Dis. 2021 Dec 6;73(11):2112-2115
pubmed: 33993265
Nature. 2021 Dec;600(7889):472-477
pubmed: 34237774
Vaccines (Basel). 2021 May 20;9(5):
pubmed: 34065294
Ann Hematol. 2021 Mar;100(3):675-689
pubmed: 33523290
Vaccines (Basel). 2021 Mar 04;9(3):
pubmed: 33806646
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Perspect Psychol Sci. 2021 Mar;16(2):191-203
pubmed: 33501900
J Infect Dis. 2021 Nov 16;224(9):1473-1488
pubmed: 33822106
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
N Engl J Med. 2020 Jun 11;382(24):2368-2371
pubmed: 32302076
Clin Microbiol Infect. 2021 Sep;27(9):1242-1249
pubmed: 34116205